Variant Bio has entered a multi-year research partnership with Novo Nordisk, focusing on the identification of new targets to treat metabolic conditions. Leveraging Variant’s ‘VB-Inference ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes. By Brendan Borrell When Stephane Castel first ...

Genetic material is deeply personal, and powerful. Now, Seattle-based Variant Bio has a plan to develop drugs for metabolic disorders, using data collected from Indigenous populations. In exchange ...

Collaboration leverages Variant Bio's innovative VB-Inference Platform and expertise partnering with global populations Commercial terms include an upfront payment and additional near-term R&D ...

Commercial terms include an upfront payment and additional near-term R&D funding totaling up to $50 million, plus potential option and milestone payments SEATTLE, Jan. 7, 2025 /PRNewswire ...

As a result, there is still an unmet need in this space," said David Moller, Chief Scientific Officer at Variant Bio. "We hope that a deeper understanding of the relationships between genetic ...

A rooftop deck at Variant Bio’s Seattle offices have a view of the city’s landmark Space Needle. (Cory Parris Photo) Variant Bio today announced a partnership with Novo Nordisk for disease ...

Commercial terms include an upfront payment and additional near-term R&D funding totaling up to $50 million, plus potential option and milestone payments SEATTLE, Jan. 7, 2025 /PRNewswire/ -- Variant ...

Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.